[关键词]
[摘要]
目的 研究癫痫康胶囊联合左乙拉西坦片治疗癫痫的临床疗效。方法 选取2017年3月—2018年3月西宁市第一人民医院收治的112例癫痫患者为研究对象,利用双盲法将患者随机分为对照组和治疗组,每组各56例。对照组口服左乙拉西坦片,初始剂量5 mg/(kg·次),2次/d,之后每周增加10 mg/(kg·d),至25 mg/(kg·d)维持。治疗组在对照组治疗的基础上口服癫痫康胶囊,3粒/次,3次/d。两组患者持续治疗12周。观察两组的临床疗效,比较两组的癫痫发作频率、生活能力、智力水平和血清学指标。结果 治疗后,对照组和治疗组的总有效率分别为80.36%、92.86%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者阵挛发作、强直发作、失神发作频率均显著下降,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗组患者阵挛发作、强直发作、失神发作频率均明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者日常生活能力(ADL)评分明显降低,而韦氏智力量表(WISC-R)评分明显升高,同组治疗前后差异具有统计学意义(P<0.05);且治疗后治疗组患者ADL评分明显低于对照组,WISC-R评分明显高于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者血清S-100β蛋白(S-100β)、超敏C-反应蛋白(hs-CRP)和丙二醛(MDA)水平均明显降低,同组治疗前后差异有统计学意义(P<00.5),且治疗组患者血清S-100β、hs-CRP和MDA水平明显低于对照组,差异具有统计学意义(P<0.05)。结论 癫痫康胶囊联合左乙拉西坦片治疗癫痫具有较好的临床疗效,可改善临床症状,降低血清学指标,改善患者生活能力和智力水平,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To investigate the clinical efficacy of Dianxiankang Capsules combined with Levetiracetam Tablets in treatment of epilepsy. Methods Patients (112 cases) with epilepsy in Xining First People's Hospital from March 2017 to March 2018 were randomly divided into control and treatment groups, and each group had 56 cases. Patients in the control group were po administered with Levetiracetam Tablets, starting dosage 5 mg/(kg·time), twice daily, after that, 5 mg/(kg·d) was added weekly until 25 mg/(kg·d). Patients in the treatment group were po administered with Dianxiankang Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacies were evaluated, and the frequency of epileptic seizures, ADL scores, WISC-R scores, and serological indicators in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.36% and 92.86%, respectively, and there was difference between two groups (P<0.05). After treatment, the frequency of epileptic clonic seizure, epileptic tonic seizure, and epileptic absence seizure in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the epilepsy indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the ADL scores in two groups were significantly decreased, but the WISC-R scores in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes scores in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of S-100β, hs-CRP, and MDA in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the serological indicators levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Dianxiankang Capsules combined with Levetiracetam Tablets has clinical curative effect in treatment of epilepsy, can improve clinical symptoms, reduce serological indicators, and improve the living ability and intelligence level of patients, which has a certain clinical application value.
[中图分类号]
[基金项目]